Theravance Reports Results of Izencitinib in P-IIb Dose-Finding Induction Study for the Treatment of Ulcerative Colitis
Shots: The P-IIb dose-finding induction study evaluates izencitinib (PO, qd) vs PBO in 239 patients with a mod. to sev. active UC for 8wks. The results from the P-II study for CD is expected in late Q4’21 or early Q1’22 The study did not meet 1EPs & 2EPs of change in total Mayo score & […]